MSMyrlene Sanon

Myrlene Sanon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Myrlene Sanon has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between 1‐Year Endoscopic Outcomes and Long‐Term Clinical and Patient‐Relevant Outcomes in Crohn's Disease

    by Myrlene Sanon, Shanti Neff‐Baro, Aline Gauthier, Dominik Naessens, Marion L. Vetter, Lewin Eisele, Axel Dignass, Brian Feagan

    Background and Aims: Achieving endoscopic response (ER), defined as a > 50% reduction from baseline in Simple Endoscopic Score for Crohn's disease (SES‐CD) score, following induction therapy for Crohn's disease (CD) has been linked to improved 1‐year outcomes. We evaluated the impact of ER at the end of maintenance (EOM) on long‐term clinical outcomes. Methods: Data from a Phase 3 randomized trial (IM‐UNITI, ustekinumab) and a Phase 2 trial (GALAXI 1, guselkumab and ustekinumab) were analyzed using multivariable statistical methods. The relationship between ER at the EOM (Week 48) and outcomes at Week 96, including clinical remission, hospitalization, and surgery, was assessed. Results: Endoscopic and clinical remission data at the EOM were available for 461 patients. ER at EOM was significantly associated with higher odds of clinical remission (odds ratio [OR] = 1.91; p < 0.05) at Week 96. ER was also linked to reduced inflammatory burden, with higher odds of C‐reactive protein normalization (OR = 2.19; p < 0.005). Forty‐one patients were hospitalized or required surgery during the long‐term extension, with higher event rates among those without ER at the EOM ( p = 0.1237). Conclusions: ER after 48 weeks of maintenance therapy was associated with a greater likelihood of clinical remission and improved quality of life at 1 year. Data also suggest lower hospitalization and surgery rates for those who achieve ER. Larger studies are needed to substantiate long‐term reductions in hospitalizations and surgeries.


  • Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource

    by Kaung Yan, Sudheer Kumar Vuyyuru, Adam Taylor, Grazziela Figueredo, Tim Raine, Myrlene Sanon, Dominik Naessens, Chinmay Munje, Gordon W Moran

    Background and Aims: It is unclear if a sustained response to the first advanced therapy affects the long-term risk of hospitalization in patients with inflammatory bowel disease (IBD). We have undertaken a retrospective analysis of clinical outcomes using the National Institute for Health and Care Research (NIHR) IBD BioResource database. Methods: We included adult patients (≥18 years old) with Crohn disease (CD) or ulcerative colitis (UC) who received treatment with at least 1 advanced therapy. Treatment response was defined as clinical response or remission for 12 months or longer. The outcome was the incidence of IBD-related long-term risk of hospitalization, defined as admission for IBD-related surgery or disease exacerbation requiring intravenous corticosteroids over the duration of follow-up. Results: A total of 15 531 patients (CD, 10 024; and UC, 5507) were included in the analysis. Overall, 82% of CD patients and 75.2% of UC patients experienced treatment response to their first advanced treatment. Treatment response to the first advanced therapy initiated was significantly associated with a lower long-term risk of hospitalization in both CD (odds ratio [OR], 0.826; 95% CI, 0.797-0.857) and UC (OR, 0.975; 95% CI, 0.954-0.997). The median (IQR) time (years) for hospitalization In CD responders was 2 (1-4) years and in CD nonresponders was 1.17 (1-3) years, P < .0001 and in UC responders was 1.38 (0.85-3) years and in UC nonresponders was 1 (0.65-2) years, P < .0019. Conclusions: Treatment response to the first advanced treatment initiated is significantly associated with a lower long-term risk of hospitalization for IBD. Choosing the best therapy the first time may improve long-term outcomes.


  • Open Access

    One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn’s Disease: A Network Meta-Analysis

    by Tim Disher, Dominik Naessens, Myrlene Sanon, Ashley Bonner, Jenna Ellis, Meaghan Bartlett, Becky Hooper, Zijiang Yang, Jessica R. Allegretti, Axel Dignass

    Introduction This study used network meta-analysis (NMA) to evaluate the comparative efficacy of available advanced therapies for moderately to severely active Crohn’s disease (CD) versus the IL-23 inhibitor guselkumab. Methods A systematic literature review was conducted to identify randomized controlled trials (RCTs) of advanced therapies in moderately to severely active CD. Bayesian NMAs were conducted for outcomes of clinical response, clinical remission, endoscopic response, and a combined outcome of clinical remission with endoscopic response, at the end of the maintenance phase (up to 1 year). Primary analyses included patients with varied prior inadequate treatment responses, with additional analyses conducted for specific subgroups. Re-randomized trials were normalized in several cases to mimic a standard treat-through design, incorporating data from additional sources, when necessary, for patients who had an inadequate response or experienced a delayed response following induction. Results Of the 58 RCTs identified, 13 with maintenance endpoint data were ultimately included in the NMAs. Guselkumab 100 mg and 200 mg were more likely to be effective versus several comparators. Guselkumab 200 mg demonstrated significantly greater efficacy versus infliximab 10 mg/kg every 8 weeks and upadacitinib 30 mg daily for clinical response and clinical remission. For endoscopic response, guselkumab 200 mg showed significantly greater efficacy than ustekinumab, adalimumab, and upadacitinib. Significance was also noted versus ustekinumab on the combined outcome of clinical remission with endoscopic response. Similarly, guselkumab 100 mg demonstrated efficacy versus comparators across analyses. Guselkumab achieved higher rankings based on surface under the cumulative ranking curve. Findings of primary analyses within mixed populations were generally corroborated by subpopulation analyses. Conclusion Results of this NMA in moderately to severely active CD indicate a higher likelihood of guselkumab achieving each clinical and endoscopic endpoint analyzed at the end of the maintenance phase versus other advanced therapies assessed.


  • Open Access

    Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn’s Disease in the United States and Europe

    by Jim Kershaw, Myrlene Sanon, Sumesh Kachroo, Sophie Barlow, Dominik Naessens, Cynthia J Willey, Grace O’nEill, Timothy Hoops

    Background: Despite a wide range of available treatments, there is limited evidence as to why significant numbers of Crohn’s disease (CD) patients do not achieve disease remission or continue to have residual symptom burden. We aimed to quantify the impact of this suboptimal treatment on patient symptom incidence and severity, quality of life (QoL), and work impairment. Methods: Data were derived from the Adelphi Real World CD Disease Specific Programme, a cross-sectional survey of CD patients and their treating physicians in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021. Physicians reported on patients’ clinical history, disease status, symptom load, and treatment. Patients reported their QoL and activity impairment using the EQ-5D-5L and Work Productivity and Activity Impairment measures. Patients were divided into remitters, partial remitters, and non-remitters. Multivariate regression models were used to assess the impact of remission status on clinical and QoL outcomes. Results: Of 1786 patients, 24.1% were remitters, 53.2% were partial remitters, and 22.7% were non-remitters. Partial remitters and non-remitters had a significantly higher symptom load than remitters (P < .05), and non-remitters were up to 15 times more likely to experience key symptoms than remitters. Both non-remitters and partial remitters were also significantly more likely to have increased symptom severity (P < .05). Non-remitters were more likely to have switched treatment and received more treatment lines, as well as having significantly worse QoL, than remitters. Conclusions: Suboptimal treatment response was associated with increased symptoms and QoL burden. Despite the increased burden experienced, partial remitters were not more likely to switch or receive more treatment lines than remitters, demonstrating the need to initiate effective therapy.


  • Open Access

    Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey

    by Steven N. Michalopoulos, Marjolaine Gauthier-Loiselle, Myrlene Sanon Aigbogun, Elizabeth Serra, Rebecca Bungay, Diana Clynes, Martin Cloutier, Erin Kahle, Annie Guérin, Youssef M.K. Farag, et al.


  • Open Access

    The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study

    by Kenneth Rockwood, Myrlene Sanon Aigbogun, Justin Stanley, Helen Wong, Taylor Dunn, Chère A T Chapman, Susan E Howlett, Maia Miguelez, Lisa McGarrigle, Ross A Baker

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet